Unlocking the Potential of CAMK2D as a Drug Target and Biomarker

Target Name: CAMK2D

NCBI ID: G817

CAMK2D

Unlocking the Potential of CAMK2D as a Drug Target and Biomarker

CaM kinase II delta subunit (CAMK2D) is a protein that plays a crucial role in cell signaling pathways, particularly in the regulation of cell adhesion, migration, and invasion. It is a member of the CaM kinase II family, which is known for its ability to regulate various cellular processes including cell proliferation, differentiation, and survival. The CaM kinase II delta subunit is expressed in most tissues and cells, making it an attractive drug target and biomarker for various diseases.

Disease-Oriented Research of CAMK2D

CAMK2D has been extensively studied in the context of various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its role in these diseases has led to a growing interest in its potential as a drug target or biomarker.

CAMK2D's Role in Cancer

CAMK2D has been shown to play a negative role in cancer cell growth and progression. It has been shown to inhibit the formation of new blood vessels, which contributes to the tumor's growth and the development of cancer stem cells. Additionally, CAMK2D has been shown to promote the programmed cell death (apoptosis) in cancer cells, which is a critical mechanism for the tumor to eliminate damaged or dysfunctional cells.

CAMK2D's Role in Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurogenic gradients. CAMK2D has been shown to be involved in the regulation of neurodegenerative diseases.

CAMK2D's Role in Developmental Disorders

Developmental disorders, such as Down syndrome, are characterized by the presence of developmental delays, intellectual disabilities, and unique behavioral profiles. CAMK2D has been shown to play a role in the development and progression of developmental disorders.

CAMK2D as a Drug Target

The potential of CAMK2D as a drug target is based on its unique structure and its ability to interact with various signaling pathways. CAMK2D can interact with several protein signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

CAMK2D can be a useful drug target for treating various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, inhibiting the activity of CAMK2D has been shown to be effective in treating various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, inhibiting the activity of CAMK2D has been shown to be effective in treating neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

CAMK2D as a Biomarker

CAMK2D has also been shown to be a useful biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The levels of CAMK2D have been shown to be elevated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. This increased expression of CAMK2D can be used as a diagnostic tool and as a target for diagnostic biomarkers.

Conclusion

CAMK2D is a protein that has been extensively studied in the context of various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its role in these diseases has led to a growing interest in its potential as a drug target or biomarker. The inhibition of CAMK2D activity has been shown to be effective in treating various types of cancer, including breast, ovarian, and colorectal cancer, as well as

Protein Name: Calcium/calmodulin Dependent Protein Kinase II Delta

Functions: Calcium/calmodulin-dependent protein kinase involved in the regulation of Ca(2+) homeostatis and excitation-contraction coupling (ECC) in heart by targeting ion channels, transporters and accessory proteins involved in Ca(2+) influx into the myocyte, Ca(2+) release from the sarcoplasmic reticulum (SR), SR Ca(2+) uptake and Na(+) and K(+) channel transport. Targets also transcription factors and signaling molecules to regulate heart function. In its activated form, is involved in the pathogenesis of dilated cardiomyopathy and heart failure. Contributes to cardiac decompensation and heart failure by regulating SR Ca(2+) release via direct phosphorylation of RYR2 Ca(2+) channel on 'Ser-2808'. In the nucleus, phosphorylates the MEF2 repressor HDAC4, promoting its nuclear export and binding to 14-3-3 protein, and expression of MEF2 and genes involved in the hypertrophic program (PubMed:17179159). Is essential for left ventricular remodeling responses to myocardial infarction. In pathological myocardial remodeling acts downstream of the beta adrenergic receptor signaling cascade to regulate key proteins involved in ECC. Regulates Ca(2+) influx to myocytes by binding and phosphorylating the L-type Ca(2+) channel subunit beta-2 CACNB2. In addition to Ca(2+) channels, can target and regulate the cardiac sarcolemmal Na(+) channel Nav1.5/SCN5A and the K+ channel Kv4.3/KCND3, which contribute to arrhythmogenesis in heart failure. Phosphorylates phospholamban (PLN/PLB), an endogenous inhibitor of SERCA2A/ATP2A2, contributing to the enhancement of SR Ca(2+) uptake that may be important in frequency-dependent acceleration of relaxation (FDAR) and maintenance of contractile function during acidosis (PubMed:16690701). May participate in the modulation of skeletal muscle function in response to exercise, by regulating SR Ca(2+) transport through phosphorylation of PLN/PLB and triadin, a ryanodine receptor-coupling factor. In response to interferon-gamma (IFN-gamma) stimulation, catalyzes phosphorylation of STAT1, stimulating the JAK-STAT signaling pathway (By similarity)

The "CAMK2D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CAMK2D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets